drugset / Trial / NCT02266927

A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)

NCT02266927

Phase 1 Completed 28 enrolled Optinose US Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

To compare the systemic exposure of a single dose of 400 µg of OPTINOSE FLUTICASONE with 440 µg of Flovent® HFA (fluticasone propionate) Inhalation Aerosol in asthmatic subjects.

Timeline

Start
2014-09
Primary completion
2015-03
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 400 ug Intranasal
Comparator Fluticasone propionate Other / unclassified 440 ug Intranasal
Comparator Fluticasone propionate Other / unclassified 440 ug Inhaled

Indications